- Clinical deep remission required zero tender/swollen joints plus normal CRP and ESR levels.
- At 5 years, sustained remission rates were 63% with clinical deep remission vs 38% without it.
- Among patients without clinical deep remission, treatment tapering was associated with an 8.5-fold higher relapse hazard.
- The effect of tapering on relapse risk was significantly attenuated in patients who achieved clinical deep remission.
- The observational, single-center study included 145 patients, most of whom were anti-CCP positive and treated with conventional synthetic DMARDs.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
